Asciminib Monotherapy in Patients with CML-CP without BCR::ABL1 T315I Mutations Treated with at Least Two Prior TKIs: 4-Year Phase 1 Safety and Efficacy Results

Scientists reported updated results of a Phase I, open-label, nonrandomized trial, NCT02081378, assessing the safety, tolerability, and antileukemic activity of asciminib monotherapy 10–200 mg once or twice daily in 115 patients with chromosome–positive chronic-phase chronic myeloid leukemia without T315I .